The supplemental new drug application (sNDA) submitted to the FDA adds the company’s goal of expanding the Vascepa manufacturing supply chain.
Amarin chairman and chief executive officer Joseph Zakrzewski said, "A key goal of Amarin is to expand our global supply chain to support expected Vascepa demand, diversify our supply base and ensure cost-efficient supply."
Amarin aims to protect commercial potential of Vascepa through patent protection, regulatory exclusivity along with taking gain from manufacturing barriers to entry, according to the company.